New insights into the diagnosis and treatment of dry eye

Murat Dogru, Kazuo Tsubota

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Over the past decade, numerous advances have been made in relation to dry eye diagnostic markers, technologies, and treatment options. The mainstay of treatment of dry eye is the use of artificial tear solutions and punctum plugs. A goal is the development of agents that provide symptomatic treatment and, at the same time, improve ocular surface keratinization. It is the authors' opinion that the functional visual acuity tester and the new tear stability analysis system will be widely used to improve diagnosis and evaluate treatment outcomes in KCS. Advances in treatment will utilize anti-inflammatory agents, immune suppressants such as Cyclosporin A and FK-506, growth hormones, androgens, topical mucins and ocular surface stimulating drugs, like INS365. Although aqueous-deficient dry eye is most commonly not associated with Sjogren syndrome (SS), aqueous-deficient dry eye is often most severe in patients with SS; thus, this article focuses mainly on SS-associated dry eye.

Original languageEnglish
Pages (from-to)59-75
Number of pages17
JournalOcular Surface
Volume2
Issue number2
Publication statusPublished - 2004 Apr

Fingerprint

Sjogren's Syndrome
Therapeutics
Tacrolimus
Mucins
Tears
Cyclosporine
Androgens
Growth Hormone
Visual Acuity
Anti-Inflammatory Agents
Technology
Pharmaceutical Preparations

Keywords

  • Anti-inflammatory agents
  • Aqueous deficiency
  • Autoimmune disorder
  • Dry eye syndrome
  • Heredity
  • Inflammation
  • Keratoconjunctivitis sicca
  • Sjogren syndrome
  • Tear stability analysis system
  • Visual acuity meter

ASJC Scopus subject areas

  • Ophthalmology

Cite this

New insights into the diagnosis and treatment of dry eye. / Dogru, Murat; Tsubota, Kazuo.

In: Ocular Surface, Vol. 2, No. 2, 04.2004, p. 59-75.

Research output: Contribution to journalArticle

@article{1c7f22b4e10349f0a7740f9e11ccac3a,
title = "New insights into the diagnosis and treatment of dry eye",
abstract = "Over the past decade, numerous advances have been made in relation to dry eye diagnostic markers, technologies, and treatment options. The mainstay of treatment of dry eye is the use of artificial tear solutions and punctum plugs. A goal is the development of agents that provide symptomatic treatment and, at the same time, improve ocular surface keratinization. It is the authors' opinion that the functional visual acuity tester and the new tear stability analysis system will be widely used to improve diagnosis and evaluate treatment outcomes in KCS. Advances in treatment will utilize anti-inflammatory agents, immune suppressants such as Cyclosporin A and FK-506, growth hormones, androgens, topical mucins and ocular surface stimulating drugs, like INS365. Although aqueous-deficient dry eye is most commonly not associated with Sjogren syndrome (SS), aqueous-deficient dry eye is often most severe in patients with SS; thus, this article focuses mainly on SS-associated dry eye.",
keywords = "Anti-inflammatory agents, Aqueous deficiency, Autoimmune disorder, Dry eye syndrome, Heredity, Inflammation, Keratoconjunctivitis sicca, Sjogren syndrome, Tear stability analysis system, Visual acuity meter",
author = "Murat Dogru and Kazuo Tsubota",
year = "2004",
month = "4",
language = "English",
volume = "2",
pages = "59--75",
journal = "Ocular Surface",
issn = "1542-0124",
publisher = "Ethis Communications, Inc.",
number = "2",

}

TY - JOUR

T1 - New insights into the diagnosis and treatment of dry eye

AU - Dogru, Murat

AU - Tsubota, Kazuo

PY - 2004/4

Y1 - 2004/4

N2 - Over the past decade, numerous advances have been made in relation to dry eye diagnostic markers, technologies, and treatment options. The mainstay of treatment of dry eye is the use of artificial tear solutions and punctum plugs. A goal is the development of agents that provide symptomatic treatment and, at the same time, improve ocular surface keratinization. It is the authors' opinion that the functional visual acuity tester and the new tear stability analysis system will be widely used to improve diagnosis and evaluate treatment outcomes in KCS. Advances in treatment will utilize anti-inflammatory agents, immune suppressants such as Cyclosporin A and FK-506, growth hormones, androgens, topical mucins and ocular surface stimulating drugs, like INS365. Although aqueous-deficient dry eye is most commonly not associated with Sjogren syndrome (SS), aqueous-deficient dry eye is often most severe in patients with SS; thus, this article focuses mainly on SS-associated dry eye.

AB - Over the past decade, numerous advances have been made in relation to dry eye diagnostic markers, technologies, and treatment options. The mainstay of treatment of dry eye is the use of artificial tear solutions and punctum plugs. A goal is the development of agents that provide symptomatic treatment and, at the same time, improve ocular surface keratinization. It is the authors' opinion that the functional visual acuity tester and the new tear stability analysis system will be widely used to improve diagnosis and evaluate treatment outcomes in KCS. Advances in treatment will utilize anti-inflammatory agents, immune suppressants such as Cyclosporin A and FK-506, growth hormones, androgens, topical mucins and ocular surface stimulating drugs, like INS365. Although aqueous-deficient dry eye is most commonly not associated with Sjogren syndrome (SS), aqueous-deficient dry eye is often most severe in patients with SS; thus, this article focuses mainly on SS-associated dry eye.

KW - Anti-inflammatory agents

KW - Aqueous deficiency

KW - Autoimmune disorder

KW - Dry eye syndrome

KW - Heredity

KW - Inflammation

KW - Keratoconjunctivitis sicca

KW - Sjogren syndrome

KW - Tear stability analysis system

KW - Visual acuity meter

UR - http://www.scopus.com/inward/record.url?scp=24644457694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644457694&partnerID=8YFLogxK

M3 - Article

C2 - 17216080

AN - SCOPUS:24644457694

VL - 2

SP - 59

EP - 75

JO - Ocular Surface

JF - Ocular Surface

SN - 1542-0124

IS - 2

ER -